CCCC Revenue Drops 46%
C4 Therapeutics (NASDAQ:CCCC), a clinical-stage biopharmaceutical company specializing in targeted protein degradation therapies, released second quarter results on August 7, 2025. GAAP revenue for Q2 2025 was $6.5 million, slightly below analyst estimates of $6.55 million and down from $12.0 million in the prior-year period. Net loss widened year over year, with GAAP earnings per share at $(0.37), modestly better than the consensus expectation of a $(0.38) loss. Over the quarter, management emphasized major advancements in its clinical pipeline, especially its lead drug candidate, but financial performance highlighted continued reliance on milestone payments and the challenges of rising development costs.
Source: Analyst estimates for the quarter provided by FactSet.
C4 Therapeutics is focused on discovering and developing targeted protein degraders. These are drugs designed to break down disease-causing proteins, an approach aimed at treating cancers and other serious illnesses. The company’s lead asset, cemsidomide, targets multiple myeloma, a cancer of plasma cells, while other candidates include therapies for non-Hodgkin lymphoma and specific types of genetically driven cancers.
Source Fool.com
